Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction

[1]  P. Chang,et al.  Heart failure with preserved ejection fraction: an ongoing enigma. , 2014, Cardiology clinics.

[2]  J. Januzzi,et al.  Biomarkers and diagnostics in heart failure. , 2013, Biochimica et biophysica acta.

[3]  P. Benkert,et al.  Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. , 2013, Journal of cardiac failure.

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  A. Cohen-Solal,et al.  Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. , 2013, International journal of cardiology.

[6]  M. Redfield,et al.  Acute Heart Failure with Preserved Ejection Fraction: Unique Patient Characteristics and Targets for Therapy , 2013, Current Heart Failure Reports.

[7]  G. Grollier,et al.  Perspectives on the Value of Biomarkers in Acute Cardiac Care and Implications for Strategic Management , 2013, Biomarker insights.

[8]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[9]  S. Manzano-Fernández,et al.  Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure , 2012, Cardiology.

[10]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[11]  D. Sawyer,et al.  Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes. , 2012, The open biomarkers journal.

[12]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[13]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.

[14]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term OutcomesClinical Perspective , 2011 .

[15]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[16]  S. Manzano-Fernández,et al.  Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. , 2011, The American journal of cardiology.

[17]  T. Mueller,et al.  Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[18]  Richard T. Lee,et al.  Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling , 2009, Circulation. Heart failure.

[19]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[20]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[21]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[22]  E. Braunwald.  Biomarkers in heart failure. , 2008, The New England journal of medicine.

[23]  T. Mueller,et al.  Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. , 2008, Clinical chemistry.

[24]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[25]  M. Leblanc,et al.  Biomarkers in Acute Kidney Injury , 2008, Biomarker insights.

[26]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[27]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[28]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[29]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[30]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[31]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[32]  R. Vasan,et al.  Novel markers for heart failure diagnosis and prognosis , 2005, Current opinion in cardiology.

[33]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[34]  Richard T. Lee,et al.  Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.

[35]  M. Itakura,et al.  Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. , 1999, European journal of biochemistry.

[36]  M. Nicklin,et al.  Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. , 1999, Genomics.